Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ADVICOR

« Back to Dashboard
Advicor is a drug marketed by Abbvie and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and four Paragraph IV challenges.

This drug has twenty-nine patent family members in ten countries.

The generic ingredient in ADVICOR is lovastatin; niacin. There are thirty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the lovastatin; niacin profile page.

Summary for Tradename: ADVICOR

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list8

Pharmacology for Tradename: ADVICOR

Clinical Trials for: ADVICOR

Phase II Trial - Breast Cancer Chemoprevention by Lovastatin
Status: Terminated Condition: Breast Cancer

The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
Status: Completed Condition: Intermittent Claudication; Peripheral Vascular Disease

Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication
Status: Completed Condition: Intermittent Claudication; Peripheral Vascular Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249-004Apr 27, 2006RXYes6,469,035<disabled> <disabled>
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249-003Dec 17, 2001RXYes6,080,428<disabled> <disabled>
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249-002Dec 17, 2001RXYes6,469,035<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ADVICOR

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249-001Dec 17, 20016,676,967<disabled>
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249-002Dec 17, 20016,129,930<disabled>
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249-001Dec 17, 20016,746,691<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ADVICOR

Drugname Dosage Strength RLD Submissiondate
lovastatin and niacinExtended-release Tablets40 mg/1000 mgAdvicor11/19/2009
lovastatin and niacinExtended-release Tablets20 mg/750 mgAdvicor12/17/2008
lovastatin and niacinExtended-release Tablets20 mg/500 mgAdvicor9/22/2008
lovastatin and niacinExtended-release Tablets20 mg/1000 mgAdvicor5/22/2008

Non-Orange Book Patents for Tradename: ADVICOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,129,930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night<disabled in preview>
7,998,506Nicotinic acid compositions for treating hyperlipidemia and related methods therefor<disabled in preview>
6,818,229 Intermediate release nicotinic acid compositions for treating hyperlipidemia<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ADVICOR

Country Document Number Publication Date
Canada2297756Feb 11, 1999
World Intellectual Property Organization (WIPO)9906052Feb 11, 1999
Norway994275Oct 11, 1999
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc